Shared from twixb · endpts.com
The Health Tech team conducted discussions at the Financial Times’ US Pharma and Biotech Summit, in partnership with Endpoints News, centering on key topics in the pharmaceutical and biotech sectors.
The content provided does not contain specific insights relevant to healthtech, biotech, or related fields. Please provide more detailed information from the sessions to extract a valuable takeaway for the reader.
Powered by twixb
twixb tracks your favorite blogs and social media, filters by keywords, and delivers personalized key learnings — straight to your inbox.
Recent stories curated alongside this one.
Relay Therapeutics announced promising Phase 2 data for its drug zovegalisib, resulting in a 9% increase in its shares, while Eli Lilly achieved a notable milestone by ranking first in both innovation and invention categories in a report analyzing drugmakers' R&D performance.
The U.S. Supreme Court has rejected legal challenges from major pharmaceutical companies against the Medicare drug price negotiation program, making it harder for the industry to contest the program further. Additionally, the White House has expanded the TrumpRx prescription drug discount platform by adding over 600 generic drugs through partnerships with Mark Cuban's Cost Plus Drug Company, Amazon Pharmacy, and GoodRx.
Relay Therapeutics reported positive Phase 2 data for zovegalisib, a PI3Kα inhibitor, in a rare genetic disease, surpassing Wall Street expectations and broadening its research and development potential beyond breast cancer.
Relay Therapeutics' R&D chief believes that the company's PI3Kα inhibitor will establish a unique position in the market, following the release of phase 2 clinical data related to a specific blood vessel disorder.
Herantis Pharma is collaborating with Indivi to conduct a proof-of-concept clinical trial aimed at the early detection of Parkinson's disease.
